Quest Diagnostics — Apr 22, 2025 release

("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024 • Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80 SECAUCUS, N.J., April 22, 2025 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025. “In the first quarter, we delivered strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, as demand rebounded in March following weather impacts early in the quarter. Our growth was due to contributions from acquisitions and large enterprise accounts, demand for our advanced diagnostics portfolio, and expanded health plan access,” said Jim Davis, Chairman, CEO and President. “We are reaffirming our revenue and adjusted EPS guidance for the full year 2025." Three Months Ended March 31, 2025 2024 Change (dollars in millions, except per share data) Reported: Net revenues $ 2,652  $ 2,366  12.1  % Diagnostic Information Services revenues $ 2,589  $ 2,298  12.7  % Revenue per requisition 0.3  % Requisition volume 12.4  %   Organic requisition volume (0.9) % Operating income (a) $ 346  $ 300  15.4  % Operating income as a percentage of net revenues (a) 13.0  % 12.7  % 0.3  % Net income attributable to Quest Diagnostics (a) $ 220  $ 194  13.2  % Dilut